8-K
filed November 5, 2025, 6:59 PM ET
ticker MNKD
CIK 0000899460
earnings
confidence high
sentiment positive
materiality 0.80
MannKind Q3 revenue $82.1M (+17% YoY); completes scPharma acquisition
MANNKIND CORP
2025-Q3 EPS reported
$0.07
revenue$237,011,000
- Q3 2025 revenues $82.1M (+17% YoY); YTD revenues $237.0M (+14%).
- GAAP net income $8.0M ($0.03 EPS) vs $11.6M in Q3 2024; non-GAAP net income $22.4M ($0.07) +45%.
- Completed scPharmaceuticals acquisition Oct 7 with ~$133.2M cash & $250M in delayed draw term loans.
- Afrezza pediatric sBLA accepted (PDUFA May 29, 2026); FUROSCIX sNDA submitted; MNKD-101 & MNKD-201 trials advancing.
- Appointed Dr. Ajay Ahuja as CMO; cash & investments $286.3M at Sep 30.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-25-265810
- form_type
- 8-K
- ticker
- MNKD
- cik
- 0000899460
- company_name
- MANNKIND CORP
- filed_at
- 2025-11-05T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:42.545370+00:00
- generated_at
- 2026-05-17T00:29:51.771829+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- positive
- materiality_score
- 0.8
- calibrated_materiality_score
- 0.8
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-25-265810
- json_url
- https://secwatch.observer/filing/0001193125-25-265810.json
- markdown_url
- https://secwatch.observer/filing/0001193125-25-265810.md
- text_url
- https://secwatch.observer/filing/0001193125-25-265810.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/0001193125-25-265810-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/mnkd-20251105.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
YSWY
Yesway reports Q1 net income $30.2M, Adjusted EBITDA $59.2M; introduces FY2026 outlook
Yesway, Inc.
June 2, 2026, 7:35 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
VSCO
Victoria's Secret Q1 sales up 15% to $1.56B, beats guidance; raises FY2026 outlook
Victoria's Secret & Co.
June 2, 2026, 7:01 AM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
SIG
Signet Q1 sales $1.6B, SSS +1.8%; raises FY27 adjusted EPS guidance
SIGNET JEWELERS LTD
June 2, 2026, 6:54 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DG
Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance
DOLLAR GENERAL CORP
June 2, 2026, 6:54 AM ET
earnings
Items 2.02, 5.07, 7.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
HIVE
HIVE FY2026 revenue $297.8M (+158% YoY); GAAP net loss $148.4M
HIVE Digital Technologies Ltd.
June 2, 2026, 6:23 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DCI
Donaldson Q3 FY2026 sales $995.1M (+5.8%), adj. EPS $1.06 (+7.1%)
DONALDSON Co INC
June 1, 2026, 5:41 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
GMRS
GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B
GMR Solutions Inc.
June 1, 2026, 4:45 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
HPE
HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework
Hewlett Packard Enterprise Co
June 1, 2026, 4:09 PM ET
earnings
Items 1.01, 2.02, 5.02, 7.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.